http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112105724-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_806ea60b6f9611362a3c15a8f2360643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c56973daed8bcc29298b03054ce2b77
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781
filingDate 2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18c7491bd13403e1e5554bbc361b82d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd8836e45738b27a5742472e68b6ed7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f76c6de7c7ee4dbb216a75f253da9717
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a147e51515244409fb969dda1212ebd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38f0e932ac377a2e8f95be72da814aea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa7f7cef53bfa5230e399558d5614a3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab18d3b635a76e64b40b3856ee6f046d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0172e6c76a37b4decc0cc82534202518
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65a523743d023e84791e3efff391554f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58339c468c3111b14b5038980f6159e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21754d9c3d4accf92466ea3221db4550
publicationDate 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-112105724-A
titleOfInvention Construction method of antigen-presenting cell line without endogenous HLA gene background, antigen-presenting cell line and use thereof
abstract Provided is a method for constructing an antigen-presenting cell line without an endogenous HLA gene background, comprising: using a CRISPR/Cas9 gene editing system to knock out the endogenous HLA-C gene in a C1R antigen-presenting cell with a single HLA type, Wherein the C1R antigen-presenting cells comprise HLA-A, HLA-B and HLA-C genes, wherein HLA-A is not expressed, and HLA-B is substantially not expressed; and the antigen presentation without endogenous HLA gene background obtained by the method cell line.
priorityDate 2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107249605-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003165835-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6558671-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017327795-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ03181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419564680
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35396
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3107
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18475210
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3105
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454364176
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3106
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22094277

Total number of triples: 38.